Cocrystal pharma, inc. (COCP)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Dec'10
Assets
Current assets:
Cash

21,686

7,418

5,994

7,474

8,571

2,723

4,684

-

-

748

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash and cash equivalents

-

-

-

-

-

-

-

6,841

1,249

-

1,345

3,451

1,555

3,605

5,906

5,022

10,242

9,276

12,413

15,781

14,257

3,970

3,006

4,074

2,599

1,034

529

354

92

8

82

174

76

416

781

1,839

251

Restricted cash

50

50

50

50

50

29

29

29

29

29

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

35

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts receivable

644

644

768

914

1,078

-

-

-

-

-

0

0

0

21

16

13

16

32

12

17

146

122

-

-

-

0

50

1,489

563

-

919

1,261

1,036

523

1,826

1,671

1,397

Marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,975

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

993

-

2,500

5,719

7,285

-

-

-

-

-

-

-

-

-

-

-

-

Assets of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,661

-

-

-

-

-

-

-

Inventories

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,726

1,524

1,678

-

2,151

2,371

1,741

1,819

3,387

2,838

2,501

Prepaid expenses and other current assets

202

169

201

95

169

191

278

229

203

105

240

196

251

517

625

688

486

441

632

364

192

144

116

156

153

139

207

202

188

17

489

562

381

145

60

94

43

Mortgage note receivable

-

-

-

-

-

-

0

0

0

1,294

1,294

1,294

1,294

1,294

-

-

-

170

-

-

-

165

-

148

-

0

-

-

-

-

-

-

-

-

-

-

-

Mortgage note receivable, current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

208

213

172

-

168

167

166

-

181

-

-

-

311

-

-

-

-

-

-

-

-

-

-

Total current assets

22,582

8,281

7,013

8,533

9,868

2,943

4,991

7,099

1,481

2,176

2,879

4,941

3,100

5,472

6,755

5,936

10,916

9,919

13,225

16,329

15,754

6,376

5,803

10,097

10,037

1,173

2,826

3,571

2,522

6,687

3,643

4,368

3,236

2,904

6,055

6,443

4,193

Property and equipment, net

494

431

459

368

386

384

31

95

109

119

243

268

287

280

320

357

392

430

369

215

245

284

314

361

412

469

3,133

3,262

3,371

552

3,344

3,409

3,484

3,342

3,186

3,139

3,262

Deposits

-

-

-

-

-

-

49

31

31

31

31

31

31

31

-

-

-

31

-

-

-

31

-

-

-

19

-

-

-

-

-

-

-

-

-

-

-

Mortgage note receivable, long-term portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,354

-

-

-

2,431

-

2,478

-

0

-

-

-

-

-

-

-

-

-

-

-

In-process research and development

-

-

-

-

-

-

53,905

53,905

53,905

53,905

53,905

53,905

53,905

53,905

-

-

-

146,301

-

-

-

184,966

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Marketable securities, long-term portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,043

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deposits

39

50

50

50

40

40

-

-

-

-

-

-

-

-

54

56

31

-

31

31

31

-

22

31

32

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease right-of-use assets, net (including $40 to related party)

634

677

720

761

802

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Mortgage note receivable, long-term portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,276

2,303

2,333

-

2,374

2,393

2,412

-

2,453

-

-

-

-

-

-

-

-

-

-

-

-

-

-

In process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

146,301

146,301

146,301

-

184,966

184,966

184,966

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Due from purchaser of Glyderm assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

400

-

-

-

-

-

-

-

-

-

-

Non-marketable investment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

61

61

-

Deferred financing costs, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10

13

15

-

39

46

23

25

48

176

35

Goodwill

19,092

19,092

65,195

65,195

65,195

65,195

65,195

65,195

65,195

65,195

65,195

65,195

65,195

65,195

65,195

65,195

65,195

65,195

65,195

65,195

65,195

65,195

-

-

-

0

1,026

1,026

1,026

-

1,026

1,026

1,026

1,026

1,353

1,299

0

Intangibles, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

148

162

176

-

205

219

233

247

-

-

0

Assets of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

51

-

-

-

-

-

-

-

-

-

-

Investment in non-consolidated subsidiary

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

42

Total noncurrent assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,770

4,466

4,590

552

4,616

4,702

4,768

4,642

4,649

4,676

3,340

Total assets

42,841

28,531

73,437

74,907

76,291

68,562

124,171

126,325

120,721

121,426

122,253

124,340

122,518

124,883

220,901

220,148

225,168

224,230

266,160

269,129

268,603

259,283

11,635

12,967

10,481

1,661

7,596

8,037

7,113

7,239

8,259

9,071

8,004

7,546

10,705

11,120

7,533

Liabilities and stockholders' equity
Current liabilities:
Note payable - bank

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

2,154

2,502

Accounts payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

724

838

737

-

125

180

289

224

209

1,852

1,467

-

1,019

1,607

1,170

1,616

2,725

1,435

963

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

1,093

1,121

-

-

-

-

2,585

331

381

455

693

290

281

177

139

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,243

1,514

3,084

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

1,659

1,999

1,690

1,361

1,211

1,080

978

765

810

837

901

-

-

563

-

-

-

-

-

-

-

-

-

-

-

-

3,953

3,649

3,257

468

991

1,082

1,035

1,181

837

296

132

Deferred rent

-

-

-

-

-

-

-

-

-

31

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Current maturities of finance lease liabilities

50

103

154

204

218

214

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Current maturities of operating lease liabilities (including $59 to related party)

182

177

171

166

161

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

539

442

364

286

191

108

27

83

-

-

0

Notes payable - shareholder

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

1,099

1,099

-

1,099

1,099

1,099

1,099

1,099

-

1,102

Notes payable - shareholder

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,100

-

Convertible notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,255

2,210

1,816

1,472

1,227

1,258

1,095

2,050

2,750

2,250

0

Deferred income tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

102

102

102

0

102

102

102

102

98

69

98

Derivative liabilities

34

7

90

123

163

263

159

288

548

569

855

707

905

1,476

1,907

1,869

2,807

4,115

3,096

6,130

13,456

-

7,242

6,450

12,089

-

8,029

864

900

919

595

4,572

6,002

883

-

-

0

Derivative liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,464

-

-

-

23

-

-

-

-

-

-

-

-

-

-

-

Liabilities of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,673

-

-

-

-

-

-

-

Current portion of long term debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

165

206

206

-

194

217

241

260

284

236

277

Liabilities of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

33

-

-

-

-

-

-

-

-

-

-

Total current liabilities

1,925

2,286

2,105

1,854

1,753

1,557

1,137

1,053

1,358

1,437

1,756

1,800

2,026

2,039

3,150

3,383

5,891

6,700

4,151

7,349

14,648

9,157

7,657

6,911

12,555

386

15,287

10,428

9,212

10,820

5,421

10,048

10,773

7,278

7,796

7,542

5,078

Long-term liabilities:
Finance lease liabilities

10

14

18

21

61

117

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities (including $40 to related party)

475

523

569

614

657

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

42

47

-

-

-

-

61

-

-

-

62

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

10

17

25

-

37

-

-

63

54

57

59

-

61

62

62

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Convertible notes payable

-

-

-

-

-

-

0

0

2,039

1,007

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred tax liability

-

-

-

-

-

-

12,123

12,609

13,163

13,582

20,462

20,462

20,462

20,462

49,875

49,875

49,875

49,875

65,195

65,195

65,195

65,195

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Total long-term liabilities

485

537

587

635

718

117

12,133

12,626

15,227

14,589

20,499

20,504

20,509

20,525

49,929

49,932

49,934

49,936

65,256

65,257

65,257

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total long-term liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

65,257

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Total liabilities

2,410

2,823

2,692

2,489

2,471

1,674

13,270

13,679

16,585

16,026

22,255

22,304

22,535

22,564

53,079

53,315

55,825

56,636

69,407

72,606

79,905

74,414

7,657

6,911

12,555

386

-

-

-

-

-

-

-

-

-

-

-

Commitments and contingencies

-

-

-

-

-

-

0

0

0

-

0

0

0

0

-

-

-

0

-

-

-

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Series A convertible preferred stock, $0.001 par value; 1,000 shares authorized, 0 and 1,000 issued and outstanding

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cocrystal Discovery, Inc. Series A convertible preferred stock, $0.001 par value; 7,150 shares authorized; 0 and 7,046 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively; liquidation preference of $14,000 as of December 31, 2013, owned by Cocrystal Discovery shareholders, converted in the merger with Biozone.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,108

-

-

-

-

-

-

-

-

-

-

-

Series A convertible preferred stock, $0.001 par value; 1,000 shares authorized, issued and outstanding at December 31, 2014, issued in the merger with RFS Pharma, LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

178,218

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Long Term Debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,764

2,901

2,956

0

2,913

2,954

2,995

3,037

3,087

3,211

3,044

Stockholders' equity:
Series B convertible preferred stock, $.001 par value; 5,000 shares authorized; 10 and 1,000 shares issued and outstanding at December 31, 2015 and December 31, 2014, respectively

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Series B convertible preferred stock, $.001 par value; 5,000 shares authorized; 0 and 1,000 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

1

1

1

-

-

-

-

-

-

-

-

-

-

-

-

Common stock, $0.001 par value; 100,000 shares authorized as of March 31, 2020 and December 31, 2019; 52,141 and 35,150 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

53

36

32

32

32

30

30

30

24

24

728

727

714

24

714

704

704

694

694

694

687

123

123

122

122

0

70

69

63

63

63

61

56

55

67

67

44

Additional paid-in capital

277,628

260,932

258,128

258,021

257,908

253,949

253,676

253,556

243,708

243,419

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Additional paid-in capital

-

-

-

-

-

-

-

-

-

-

242,510

242,290

239,247

239,725

238,784

235,924

235,207

229,456

228,166

227,428

217,731

18,725

12,146

12,084

11,961

3,502

11,133

10,971

10,484

10,484

10,484

6,530

3,987

3,339

4,127

2,331

72

Accumulated other comprehensive income, net of tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

-744

-

2,235

1,827

-1,451

-

-

-

-

-

-

-

-

-

-

-

-

Accumulated other comprehensive income, net of tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

236

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Accumulated deficit

-237,250

-235,260

-187,415

-185,635

-184,120

-187,091

-142,805

-140,940

-139,596

-138,043

-143,240

-140,981

-139,978

-137,430

-71,676

-69,795

-66,568

-62,556

-32,107

-31,599

-28,976

-12,434

-10,527

-7,978

-

-12,335

-21,658

-16,349

-15,603

-14,128

-10,622

-10,523

-9,809

-6,163

-4,372

-2,032

-706

Deficit accumulated during the development stage

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

12,707

-

-

-

-

-

-

-

-

-

-

-

-

Total stockholders' equity

40,431

25,708

70,745

72,418

73,820

66,888

110,901

112,646

104,136

105,400

99,998

102,036

99,983

102,319

167,822

166,833

169,343

167,594

196,753

196,523

188,698

6,651

3,978

6,056

-2,074

-8,833

-10,454

-5,292

-5,056

-3,580

-74

-3,931

-5,765

-2,769

-177

366

-589

Total liabilities and stockholders' equity

42,841

28,531

73,437

74,907

76,291

68,562

124,171

126,325

120,721

121,426

122,253

124,340

122,518

124,883

220,901

220,148

225,168

224,230

266,160

269,129

268,603

259,283

11,635

12,967

10,481

1,661

7,596

8,037

7,113

7,239

8,259

9,071

8,004

7,546

10,705

11,120

7,533